New Delhi: Pharmaceutical major Ranbaxy Laboratories announced the launch of its branded product, Osovair inhalation capsules in India for the treatment of asthma on Wednesday.
"We are delighted to launch this unique product Osovair, the only combination of its type, recommended for use once-a-day," Ranbaxy Laboratories Senior VP and Regional Director Asia and CIS Sanjeev I Dani said.
The capsules are a combination of Long Acting Beta 2 Agonist (LABA) Formoterol and the new inhaled corticosteroid Ciclesonide,
It contains 12mcg of formoterol making it the first ICS/LABA combination of its type to be approved any where in the world, a company statement said.
Osovair is available in various strengths as Osovair 160 mcg, Osovair 320 mcg, depending on the severity of Asthma patients.
The capsules are to be used only with the Rheohaler, which is a capsule based multidose dry-powder inhaler.
Ranbaxy had also launched Osonide (Ciclesonide) Inhaler, a novel once-a day, product in this segment, earlier in 2006
Last year, the company also entered into an in-licensing agreement for the Indian domestic market, with the Netherlands based pharma company, Eurodrug Laboratories, for the asthma product Doxophylline - sold under the brand name 'Synasma'.
India presently has an estimated 15-20 million asthmatic patients and the estimated prevalence rate in five-11 year old children is between 10-15 per cent.
Comments
0 comment